Boehringer Ingelheim Pharmaceuticals is recalling 13,270 bottles of Catapres (clonidine hydrochloride) tablets in 0.1 mg, 0.2 mg, and 0.3 mg strengths. The recall was initiated because testing showed an 'extraneous peak' during dissolution tests, meaning the medication may not break down or be absorbed by the body as intended. These prescription tablets were distributed nationwide in the USA and Puerto Rico in 100-count bottles.
An extraneous peak during dissolution testing indicates a potential impurity or a change in how the drug dissolves, which could affect the medication's effectiveness or safety profile. While no specific injuries have been reported, inconsistent dissolution can lead to unpredictable blood pressure control.
Consultation and refund via pharmacy.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.